Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 13, 2016 6:55 AM ET


Company Overview of Sanofi US Services Inc.

Company Overview

Sanofi US Services Inc. develops, manufactures, and distributes pharmaceutical products in the United States. Its products include prescription medicines, vaccines, and other products. The company develops products in therapeutic areas including cardiovascular disease, central nervous system, internal medicine, metabolic disorders, oncology, ophthalmology, and thrombosis. It also offers biopolymer gels that allow surgeons to temporarily stop blood flow during surgery. Sanofi US Services Inc. was formerly known as Sanofi-Aventis U.S. Inc. The company was founded in 1950 and is based in Bridgewater, New Jersey. It operates pharmaceutical research sites in Bridgewater, New Jersey; Malvern, Penn...

55 Corporate Drive

Bridgewater, NJ 08807

United States

Founded in 1950





Key Executives for Sanofi US Services Inc.

Chief Executive Officer of Genzyme and President of Genzyme
Age: 60
President of Merial North America
Head of Global Supply Chain and Vice President of Global Supply Chain
Head of the North America R&D Hub and Vice President of Disposition, Safety, and Animal Research Scientific Core Platform
Senior Vice President of Global Services
Compensation as of Fiscal Year 2015.

Sanofi US Services Inc. Key Developments

Sanofi US Announces Results from Real World Outcome Study of Type 2 Diabetes

Sanofi US announced results from a real world outcome study of type 2 diabetes (T2D) patients that show switching from Lantus(R) (insulin glargine [rDNA origin] injection) to insulin detemir demonstrated higher average blood sugar levels (A1C) and lower A1C reduction over a span of 12 months compared to maintaining patients on Lantus. Alternatively, switching patients from insulin detemir to Lantus resulted in a significantly lower A1C compared to maintaining patients on insulin detemir. The study findings were presented at the 74(th) Scientific Sessions of the American Diabetes Association in San Francisco, Calif. This was a retrospective study (using an electronic medical records database) of two cohorts of adult T2D patients who had hemoglobin A1C (A1C) and weight measures at baseline that were examined between 2006 and 2012. Overall, 13,942 patients were included (female 54%, mean baseline age 58 year, average A1C 8.7%). Cohort 1 was switched to insulin detemir (DET-S) from insulin glargine or continued on insulin glargine (GLA-C) and Cohort 2 was switched to insulin glargine (GLA-S) from insulin detemir or continued on insulin detemir (DET-S). At one year follow up, in Cohort 1, compared with GLA-C patients, DET-S patients were significantly less persistent with treatment (52.5% vs 61.4%; P < 0.0001), had a significantly higher A1C (8.5% vs. 8.2%, P < 0.0001), experienced significantly less A1C reduction (-0.24% vs. -0.46%, P<0.0001) and a significantly lower proportion of patients achieved A1C <7% (21.0% vs. 26.1%, P<0.0001) and A1C <8% (45.7% vs. 53.2%, P<0.0001) despite a significantly higher proportion of DET-S patients using rapid acting insulin (57.7% vs. 52.5%, P<0.0001); there were no significant differences in hypoglycemia rate (DET-S: 2.1% vs. GLA-C: 2.1%, P=0.8894) or weight gain (DET-S: -0.35 lbs. vs. GLA-C: 0.21 lbs., P=0.3480) between the groups. In contrast, at one year follow up, in Cohort 2, compared with DET-C patients, GLA-S patients had a significantly lower A1C (GLA-S: 8.1% vs. DET-C: 8.3%, P=0.0213) and a similar A1C reduction (GLA-S: -0.6% vs. DET-C: -0.5%, P=0.0703); the proportions of patients achieving A1C <7% (GLA-S: 25.1% vs. DET-C: 23.6%, P=0.3929), A1C <8% (GLA-S: 54.8% vs. DET-C: 51.3%, P=0.0794), and hypoglycemia rates (GLA-S: 2.3% vs. DET-C: 1.7%, P=0.2314) were similar between groups; GLA-S patients had significantly greater weight gain than DET-C (GLA-S: 3.2 lbs. vs. DET-C: 0.07 lbs., P<0.001). Clinical data also needs to be considered when making treatment decisions as there are some limitations to real world outcomes data.

Sanofi US Services Inc. Presents at Latin America & Caribbean Life Sciences Conference, Mar-27-2014 04:35 PM

Sanofi US Services Inc. Presents at Latin America & Caribbean Life Sciences Conference, Mar-27-2014 04:35 PM. Venue: Graham Center Ballroom, FIU-Maidique Campus, Miami, Florida, United States. Speakers: Ana Radeljevic, Director of Biosurgery Business Planning.

Similar Private Companies By Industry

Company Name Region
Cannex Therapeutics LLC United States
FemmePharma Global Healthcare, Inc. United States
Seragon Pharmaceuticals Inc. United States
Hi-Tech Pharmacal Co., Inc. United States
Immtech Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Sanofi US Services Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at